A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors (Q34132936)

31 July 2017

title

A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors (English)

1 reference

31 July 2017

12

Jill P Mesirov

1 reference

31 July 2017

14

Keith T Flaherty

1 reference

31 July 2017

17

Levi A Garraway

1 reference

31 July 2017

11

David E Fisher

1 reference

31 July 2017

16

Pablo Tamayo

1 reference

31 July 2017

13

William C Hahn

1 reference

31 July 2017

3

Omar Abudayyeh

1 reference

31 July 2017

David J Konieczkowski

1

object named as

David J Konieczkowski

1 reference

31 July 2017

2

Cory M Johannessen

1 reference

31 July 2017

9

Ravid Straussman

1 reference

31 July 2017

15

Jennifer A Wargo

1 reference

31 July 2017

8

Michal Barzily-Rokni

1 reference

31 July 2017

6

Adriano Piris

1 reference

31 July 2017

Jong Wook Kim

4

1 reference

31 July 2017

Zachary A Cooper

5

1 reference

31 July 2017

Dennie T Frederick

7

1 reference

31 July 2017

Rizwan Haq

10

1 reference

31 July 2017

language of work or name

English

0 references

publication date

25 April 2014

1 reference

31 July 2017

1 reference

31 July 2017

volume

4

1 reference

31 July 2017

issue

7

1 reference

31 July 2017

page(s)

816-827

1 reference

MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition

31 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4154497

The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4154497

A melanocyte lineage program confers resistance to MAP kinase pathway inhibition

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4154497

Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4154497

A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4154497

Elucidating distinct roles for NF1 in melanomagenesis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4154497

Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4154497

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4154497

A landscape of driver mutations in melanoma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4154497

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4154497

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4154497

Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4154497

MicroSCALE screening reveals genetic modifiers of therapeutic response in melanoma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4154497

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4154497

Systematic identification of genomic markers of drug sensitivity in cancer cells

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4154497

Cell-selective inhibition of NF-κB signaling improves therapeutic index in a melanoma chemotherapy model

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4154497

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4154497

A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4154497

Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4154497

Human cutaneous melanomas lacking MITF and melanocyte differentiation antigens express a functional Axl receptor kinase.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4154497

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4154497

Molecular signatures database (MSigDB) 3.0.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4154497

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4154497

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4154497

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4154497

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4154497

MEK1 mutations confer resistance to MEK and B-RAF inhibition

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4154497

Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4154497

Structure-guided design of potent and selective pyrimidylpyrrole inhibitors of extracellular signal-regulated kinase (ERK) using conformational control

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4154497

Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4154497

Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4154497

Modeling genomic diversity and tumor dependency in malignant melanoma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4154497

TLR4 enhances TGF-beta signaling and hepatic fibrosis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4154497

Integrative genomic approaches identify IKBKE as a breast cancer oncogene

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4154497

Tumor necrosis factor-alpha blocks apoptosis in melanoma cells when BRAF signaling is inhibited

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4154497

BRAF mutation predicts sensitivity to MEK inhibition

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4154497

Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4154497

Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4154497

Identification of direct genomic targets downstream of the nuclear factor-kappaB transcription factor mediating tumor necrosis factor signaling.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4154497

Transcriptional regulation of the melanoma prognostic marker melastatin (TRPM1) by MITF in melanocytes and melanoma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4154497

Mutations of the BRAF gene in human cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4154497

Molecular classification of cutaneous malignant melanoma by gene expression profiling

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4154497

IkappaB kinases phosphorylate NF-kappaB p65 subunit on serine 536 in the transactivation domain

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4154497

R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4154497

Divergent gene regulation and growth effects by NF-κB in epithelial and mesenchymal cells of human skin

28 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24771846

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1158/2159-8290.CD-13-0424

1 reference

31 July 2017

1 reference

31 July 2017

1 reference